Skip to main content
. Author manuscript; available in PMC: 2015 Dec 2.
Published in final edited form as: Leukemia. 2014 May 5;29(1):27–37. doi: 10.1038/leu.2014.149

Figure 3. Combined Wee1 and TORC inhibition is effective against Ba/F3-KRAS-G12D expressing cells and induces apoptosis in mutant NRAS- and mutant KRAS-expressing cells.

Figure 3

(A-B) Approximately two-day proliferation studies performed with MK-1775, combined with AZD8055 or WYE-125132 against Ba/F3-KRAS-G12D cells. (C-E) Effect of approximately two-hr treatment of Ba/F3-KRAS-G12D cells with MK-1775 (75 nM), alone and combined with mTOR inhibitor, AZD8055 (20 nM), on phosphorylation of 4E-BP1, AKT, and S6K, as measured by immunoblotting. (F) Approximately three-day treatment of Ba/F3, Ba/F3-NRASG12D, and Ba/F3-KRAS-G12D cells, respectively, with MK-1775 (75 nM), AZD8055 (20 nM), WYE125132 (20 nM), or a combination of MK-1775+AZD8055 or MK-1775+WYE125132 prior to analysis of apoptotic death.